Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses
- PMID: 38739921
- DOI: 10.7326/M23-2781
Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses
Abstract
Background: Whether circulating sex hormones modulate mortality and cardiovascular disease (CVD) risk in aging men is controversial.
Purpose: To clarify associations of sex hormones with these outcomes.
Data sources: Systematic literature review to July 2019, with bridge searches to March 2024.
Study selection: Prospective cohort studies of community-dwelling men with sex steroids measured using mass spectrometry and at least 5 years of follow-up.
Data extraction: Independent variables were testosterone, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), dihydrotestosterone (DHT), and estradiol concentrations. Primary outcomes were all-cause mortality, CVD death, and incident CVD events. Covariates included age, body mass index, marital status, alcohol consumption, smoking, physical activity, hypertension, diabetes, creatinine concentration, ratio of total to high-density lipoprotein cholesterol, and lipid medication use.
Data synthesis: Nine studies provided individual participant data (IPD) (255 830 participant-years). Eleven studies provided summary estimates (n = 24 109). Two-stage random-effects IPD meta-analyses found that men with baseline testosterone concentrations below 7.4 nmol/L (<213 ng/dL), LH concentrations above 10 IU/L, or estradiol concentrations below 5.1 pmol/L had higher all-cause mortality, and those with testosterone concentrations below 5.3 nmol/L (<153 ng/dL) had higher CVD mortality risk. Lower SHBG concentration was associated with lower all-cause mortality (median for quintile 1 [Q1] vs. Q5, 20.6 vs. 68.3 nmol/L; adjusted hazard ratio [HR], 0.85 [95% CI, 0.77 to 0.95]) and lower CVD mortality (adjusted HR, 0.81 [CI, 0.65 to 1.00]). Men with lower baseline DHT concentrations had higher risk for all-cause mortality (median for Q1 vs. Q5, 0.69 vs. 2.45 nmol/L; adjusted HR, 1.19 [CI, 1.08 to 1.30]) and CVD mortality (adjusted HR, 1.29 [CI, 1.03 to 1.61]), and risk also increased with DHT concentrations above 2.45 nmol/L. Men with DHT concentrations below 0.59 nmol/L had increased risk for incident CVD events.
Limitations: Observational study design, heterogeneity among studies, and imputation of missing data.
Conclusion: Men with low testosterone, high LH, or very low estradiol concentrations had increased all-cause mortality. SHBG concentration was positively associated and DHT concentration was nonlinearly associated with all-cause and CVD mortality.
Primary funding source: Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668).
Conflict of interest statement
Similar articles
-
Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses.Ann Intern Med. 2023 Sep;176(9):1221-1234. doi: 10.7326/M23-0342. Epub 2023 Aug 29. Ann Intern Med. 2023. PMID: 37639720 Free PMC article. Review.
-
Serum Testosterone is Inversely and Sex Hormone-binding Globulin is Directly Associated with All-cause Mortality in Men.J Clin Endocrinol Metab. 2021 Jan 23;106(2):e625-e637. doi: 10.1210/clinem/dgaa743. J Clin Endocrinol Metab. 2021. PMID: 33059368
-
In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality.J Clin Endocrinol Metab. 2014 Jan;99(1):E9-18. doi: 10.1210/jc.2013-3272. Epub 2013 Dec 20. J Clin Endocrinol Metab. 2014. PMID: 24257908
-
Neutral associations of testosterone, dihydrotestosterone and estradiol with fatal and non-fatal cardiovascular events, and mortality in men aged 17-97 years.Clin Endocrinol (Oxf). 2016 Oct;85(4):575-82. doi: 10.1111/cen.13089. Epub 2016 May 8. Clin Endocrinol (Oxf). 2016. PMID: 27106765
-
Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.JAMA. 2006 Mar 15;295(11):1288-99. doi: 10.1001/jama.295.11.1288. JAMA. 2006. PMID: 16537739 Review.
Cited by
-
[Testosterone replacement therapy and possible side effects].Urologie. 2024 Nov;63(11):1103-1110. doi: 10.1007/s00120-024-02455-8. Epub 2024 Oct 10. Urologie. 2024. PMID: 39390141 Review. German.
-
Testosterone deficiency and chronic kidney disease.J Clin Transl Endocrinol. 2024 Aug 14;37:100365. doi: 10.1016/j.jcte.2024.100365. eCollection 2024 Sep. J Clin Transl Endocrinol. 2024. PMID: 39253627 Free PMC article. Review.
-
Testosterone therapy for functional hypogonadism in middle-aged and elderly males: current evidence and future perspectives.Hormones (Athens). 2024 Dec;23(4):801-817. doi: 10.1007/s42000-024-00587-2. Epub 2024 Jul 26. Hormones (Athens). 2024. PMID: 39060901 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous